- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07873398
Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda (FACEIT-FU)
Change in Soil-transmitted Helminth Infection Intensity Following Mass Drug Administration With Ivermectin Plus Albendazole or Albendazole Alone in Ugandan Schoolchildren: a Follow-up Study to Assess Potential Drug Resistance
The goal of this prospective follow-up study nested within an open-label randomized controlled trial is to investigate the unexpectedly high prevalence of Ascaris lumbricoides infection observed 3-4 months after school-based mass drug administration with ivermectin plus albendazole (IVM-ALB) or albendazole alone (ALB) in Kisoro District, South-Western Uganda. By assessing initial treatment response and subsequent infection dynamics, the study will help clarify whether reduced drug efficacy, suboptimal treatment coverage, reinfection, or a combination of these factors may explain the previous findings.
The main questions the study aims to answer are:
- How effective are IVM-ALB and ALB against A. lumbricoides at 3 weeks, based on egg reduction and cure rates?
- How often do A. lumbricoides and other soil-transmitted helminth infections recur by 3 months?
- How effective are the treatments against Trichuris trichiura and hookworm?
- What can genetic characterization of Ascaris eggs reveal about parasite populations and potential drug resistance markers?
The study will enrol 450 pupils aged 5-14 years from three primary schools, which participated in the previous mass drug administration evaluation. In each school, 150 pupils will be randomly assigned equally to receive a single oral dose of:
- ivermectin (200 µg/kg) plus albendazole (400 mg); or
- albendazole (400 mg) alone.
Each treatment arm will include 225 pupils overall. Children will be included regardless of baseline infection status, following parental/guardian informed consent and child assent. Other pupils will receive routine albendazole under national deworming guidelines.
Stool samples will be collected before treatment and at 3 weeks and 3 months. Duplicate Kato-Katz thick smears will quantify A. lumbricoides, T. trichiura and hookworm eggs. The primary outcome is the arithmetic mean egg reduction rate for A. lumbricoides at 3 weeks. Secondary outcomes include cure rates at 3 weeks, reinfection rates at 3 months, egg reduction and cure rates for T. trichiura and hookworm, and genetic characterization of Ascaris populations and potential resistance markers. Adverse events will be recorded through passive safety monitoring.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Jennifer Keiser, Prof.
- Telefonnummer: +41 61 284 82 18
- E-Mail: jennifer.keiser@swisstph.ch
Studieren Sie die Kontaktsicherung
- Name: Peter Steinmann, Dr.
- Telefonnummer: +41 61 284 82 29
- E-Mail: peter.steinmann@swisstph.ch
Studienorte
-
-
-
Kampala, Uganda
- Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health
-
Kontakt:
- Prudence Beinamaryo, Dr.
- Telefonnummer: +256-789-548-930
- E-Mail: prudenceb13@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Informed consent provided by parent/guardian and assent provided by pupil
- School-aged children (5-14 years) enrolled in the respective study schools
- Able and willing to provide a stool sample before and 3 weeks and 3 months post-treatment
Exclusion Criteria:
- Presence or signs of major systemic illness
- Recent use of anthelmintic drugs in the 4 weeks before treatment
- Known allergy to study medication (i.e. benzimidazoles or ivermectin)
- Participation in other clinical trials
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: IVM (200 µg/kg) + ALB (400 mg)
A single tablet of albendazole (400mg) plus 200 µg/kg of ivermectin, provided as single oral dose. |
Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
Andere Namen:
World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
Andere Namen:
|
|
Aktiver Komparator: ALB (400mg)
A single tablet of albendazole (400mg), provided as single oral dose. |
Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Egg Reduction Rates (ERRs) for A. lumbricoides infection at 3 weeks post-treatment
Zeitfenster: 3 weeks after treatment
|
Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the duplicate Kato-Katz thick smears and multiplying this number by a factor of twelve. Geometric and arithmetic mean egg counts will be calculated for the two treatment arms before and after treatment. Egg reduction for A. lumbricoides infection will then be calculated as change in egg counts from baseline to 3 weeks post-treatment. |
3 weeks after treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants A. lumbricoides egg negative at 3 weeks post-treatment (cured)
Zeitfenster: 3 weeks after treatment
|
The conversion from being egg positive pre-treatment to egg negative post-treatment, or cure rate (CR). |
3 weeks after treatment
|
|
Number of participants egg negative at 3 weeks with soil-transmitted helminth infections 3 months post-treatment (reinfected)
Zeitfenster: 3 months after treatment
|
Number of participants that converted from egg negative with Ascaris lumbricoides, Trichuris trichiura and/or hookworm infections at 3 weeks post-treatment to egg positive after 3 months. |
3 months after treatment
|
|
Number of participants with concomitant soil-transmitted helminth infections egg negative at 3 weeks post-treatment (cured)
Zeitfenster: 3 weeks after treatment
|
Number of participants that converted from egg positive with Trichuris trichiura and/or hookworm infections to egg negative after 3 weeks. |
3 weeks after treatment
|
|
Egg-reduction Rates (ERRs) against concomitant soil-transmitted helminth infections
Zeitfenster: 3 weeks after treatment
|
Percent change in arithmetic and geometric mean eggs per gram of stool from before to after treatment. ERRs will be calculated for Trichuris trichiura and hookworm infections as described in outcome 1. |
3 weeks after treatment
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Jennifer Keiser, Prof., Swiss Tropical & Public Health Institute
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Infektionen
- Parasitäre Krankheiten
- Secernentea-Infektionen
- Nematodeninfektionen
- Helminthiasis
- Ascaridida-Infektionen
- Askariasis
- Organische Chemikalien
- Heterocyclische Verbindungen
- Benzimidazoles
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Säuren, acyclisch
- Carboxylsäuren
- Makroliden
- Laktone
- Polyketide
- Carbamate
- Ivermectin
- Albendazol
Andere Studien-ID-Nummern
- 2283FU
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
There is a data sharing agreement between Swiss TPH and Uganda MoH in place. Data may be shared with other researchers upon request.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .